CN108267589A - Purposes of the mycobacterium tuberculosis protein in diagnosis of tuberculosis latent infection person and/or active tuberculosis product is prepared - Google Patents

Purposes of the mycobacterium tuberculosis protein in diagnosis of tuberculosis latent infection person and/or active tuberculosis product is prepared Download PDF

Info

Publication number
CN108267589A
CN108267589A CN201611259564.2A CN201611259564A CN108267589A CN 108267589 A CN108267589 A CN 108267589A CN 201611259564 A CN201611259564 A CN 201611259564A CN 108267589 A CN108267589 A CN 108267589A
Authority
CN
China
Prior art keywords
seq
albumen
amino acid
tuberculosis
ala
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CN201611259564.2A
Other languages
Chinese (zh)
Other versions
CN108267589B (en
Inventor
李传友
曹树辉
陈艳清
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Beijing Chest Hospital
Original Assignee
Beijing Chest Hospital
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Beijing Chest Hospital filed Critical Beijing Chest Hospital
Priority to CN202010371686.0A priority Critical patent/CN111521819B/en
Priority to CN202010371675.2A priority patent/CN111551741B/en
Priority to CN201611259564.2A priority patent/CN108267589B/en
Publication of CN108267589A publication Critical patent/CN108267589A/en
Application granted granted Critical
Publication of CN108267589B publication Critical patent/CN108267589B/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6854—Immunoglobulins
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56911—Bacteria
    • G01N33/5695—Mycobacteria
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2469/00—Immunoassays for the detection of microorganisms
    • G01N2469/20—Detection of antibodies in sample from host which are directed against antigens from microorganisms
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Abstract

The present invention provides purposes of the mycobacterium tuberculosis protein in diagnosis of tuberculosis latent infection person and/or active tuberculosis product is prepared.Method provided by the invention can detect the level of three different mycobacterium tuberculosis protein serum antibody responses simultaneously, and so as to preferably antidiastole tuberculosis latent infection person and active tuberculosis patient, sensitivity higher, specificity is more preferable.

Description

Mycobacterium tuberculosis protein is preparing diagnosis of tuberculosis latent infection person and/or activity Purposes in pulmonary tuberculosis product
Technical field
The present invention relates to biomedicine field, more particularly to mycobacterium tuberculosis protein is preparing diagnosis of tuberculosis latent infection Purposes in person and/or active tuberculosis product.
Background technology
The tuberculosis as caused by mycobacterium tuberculosis is still one of disease of serious threat human health, is defended according to the world The newest report of raw tissue, the new hair cases of tuberculosis in the whole world in 2015 is 10,400,000 people, and about 1,800,000 people die of tuberculosis, Chinese Neopathy number is 91.8 ten thousand people, and death toll is 3.8 ten thousand people, and morbidity total number of persons occupies the 4th, the world.Either in the whole world Or in China, preventing and controlling lungy are still to shoulder heavy responsibilities, particularly in some poor undeveloped states of sanitary condition Family, the infection rate of tulase are still very high.
After human infection mycobacterium tuberculosis, only about 10% people develops into active tuberculosis, and 90% people It does not fall ill, but internal tulase is not removed thoroughly, but hides in human body, referred to as tuberculosis latent infection, These people do not have any clinical symptoms, and most people is not fallen ill in life at it, and the only people of 5%--10% is in immunity of organisms During decline, generation lungy can be caused.There are about 1/3 people in the whole world at present to have infected tulase, it is seen that latent infection person people Number is numerous, it is therefore necessary to and to latent infection, person is monitored, and drug therapy is timely given when Infection Status changes, Accomplish early discovery, early treatment, this can not only prevent the deterioration of the state of an illness, reduce secondary work caused by the time for the treatment of and medication treatment With, moreover it is possible to reduce lungy send out.Therefore, the two states after tubercle bacillus affection detection and differentiate to prevention lungy There is very important effect with treatment.
There are many planting, tuberculin skin test (TST), gamma interferon discharge the detection method of tubercle bacillus affection at present Test (IGRA), traditional phlegm acid fast bacteria smear, mycobacteria fast culture, the amplification of tuberculosis specific nucleic acid segment (it is quantitative with It is qualitative) etc..TST is skin allergic reaction, and usage time is long, is mainly used for outpatient service screening, although experiment is simple and easy to do, inspection When surveying the situation of tubercle bacillus affection, BCG vaccination will appear identical as a result, can not differentiate natural infection, and specificity is not strong, In addition it can not also differentiate tuberculosis latent infection and active tuberculosis.Gamma interferon release test (IGRA) mainly detects cell Immune response, although the influence of BCG vaccination can be excluded, can not equally distinguish latent infection person and active tuberculosis patient, It is even more impossible to differentiate patient and Current Infection person after treating.And traditional phlegm acid fast bacteria smear, mycobacteria fast culture etc. are main To be used for detecting active tuberculosis patient, it is nonsensical for the judgement of latent infection state, further for clinical symptoms not allusion quotation The active tuberculosis patient of type possibly can not find bacteriology evidence.Therefore find one kind can accurately differentiate latent infection and The method of active tuberculosis has substantial worth.
It is different based on host-protective immune reaction caused after tubercle bacillus affection, it is latent for distinguishing to find blood serum designated object Volt infection and active tuberculosis have good application prospect.The serological diagnostic method of antigen-antibody reaction, due to its simplicity Property, agility, sample is easily obtained, and is concerned, now have some mycobacterium tuberculosis specific antigen be used for The serodiagnosis of tubercle bacillus affection, such as secreted protein antigen：85 complex antigens of antigen, i.e., Ag85A, Ag85B and Ag85C, etc.；Lipoprotein antigen：16kDa, 27kDa, 38kDa antigen etc.；Sugared lipid antigen：Fat arabian mannan resists Original, tuberculosaccharide lipoid antigen etc.；But these antigens are low there are positive rate in actual use, with other branch bars Bacterium is there are the problems such as cross-immunity, although having in people at highest risk's generaI investigation, therapeutic effect monitoring, judging prognosis and prompting recurrence There is certain value, but still cannot be used for making a definite diagnosis for latent tuberculosis mycobacterial infections at present.
Therefore, a kind of new method for being capable of Accurate Diagnosis tuberculosis latent infection person and active tuberculosis patient is found And marker is particularly important.
Invention content
The technical problem to be solved by the present invention is to be directed to antidiastole tuberculosis latent infection person and/or activity in the prior art The phthisical product of property there are positive rate is low, can not antidiastole the problem of going out latent tuberculosis mycobacterial infections, carry For a kind of mycobacterium tuberculosis protein in diagnosis of tuberculosis latent infection person and/or active tuberculosis product is prepared On the way.
In order to solve the above-mentioned technical problem, the technical solution of one aspect of the present invention offer is：
It is prepared by the product of detection sample moderate resistance Rv0284 antibody, anti-Rv2002 antibody and/or anti-Rv2421c antibody levels Differentiate, the purposes in diagnosis and/or screening tuberculosis latent infection and/or active tuberculosis product.
In the inventive solutions, arbitrary detection sample moderate resistance Rv0284 antibody, anti-Rv2002 antibody can be used And/or the product of anti-Rv2421c antibody levels is used to prepare discriminating, diagnosis and/or screening tuberculosis latent infection and/or activity Phthisical product.
Preferably, above-mentioned detection sample moderate resistance Rv0284 antibody, anti-Rv2002 antibody and/or anti-Rv2421c antibody water Rv0284 albumen, Rv2002 albumen and/or Rv2421c albumen are included in flat product.
It is highly preferred that the Rv0284 albumen is the amino acid sequence shown in SEQ ID NO.1 or shown in SEQ ID NO.1 Albumen shown in the engineered rear and SEQ ID NO.1 of one or several amino acid residues in row has the protein of identical function； The Rv2002 albumen is one or several ammonia in the amino acid sequence shown in SEQ ID NO.2 or shown in SEQ ID NO.2 Albumen has the protein of identical function after base acid residue is engineered and shown in SEQ ID NO.2；The Rv2421c albumen is After one or several amino acid residues in amino acid sequence shown in SEQ ID NO.3 or shown in SEQ ID NO.3 are engineered There is the protein of identical function with albumen shown in SEQ ID NO.3.
Term " transformation " described above can use it is arbitrary in the prior art to the remodeling method of protein, including but it is unlimited In substitution and/or addition and/or missing to amino acid residue, so as to form the derivative of original protein.
Preferably, the detection can be detection method any appropriate in the prior art, but preferably, the inspection The method of survey can be enzyme-linked immunosorbent assay, aggegation experiment, precipitation experiments, E garlands are tested, small phagocytosis is tested, immune glimmering Light experiment, colloidal gold immunochromatographimethod experiment, dot immuno gold filtration assay experiment and/or electrochemiluminescence assay.It is highly preferred that at this In one embodiment of invention, the method for the detection is enzyme-linked immunosorbent assay.
Preferably, the sample can be any appropriate sample obtained from detected object.But preferably, institute It states sample and includes serum, blood plasma, saliva, urine, Pleural effusions and/or cerebrospinal fluid.It is highly preferred that in one embodiment of the present invention In formula, the sample is serum.
Another aspect of the present invention there is provided one kind for differentiate, diagnose and/or screening tuberculosis latent infection and/or The mark compositions of active tuberculosis, the mark compositions are by anti-Rv0284 antibody, anti-Rv2002 antibody and/or resist Rv2421c antibody forms；
Wherein, the Rv0284 is one in the amino acid sequence shown in SEQ ID NO.1 or shown in SEQ ID NO.1 Albumen has the protein of identical function after a or several amino acid residues are engineered and shown in SEQ ID NO.1；It is described Rv2002 is one or several amino acid residues in the amino acid sequence shown in SEQ ID NO.2 or shown in SEQ ID NO.2 Albumen has the protein of identical function after engineered and shown in SEQ ID NO.2；The Rv2421c is SEQ ID NO.3 institutes Show or SEQ ID NO.3 shown in amino acid sequence in one or several amino acid residues it is engineered after and SEQ ID NO.3 Shown albumen has the protein of identical function.
Another aspect of the present invention differentiates, diagnoses and/or sieves in preparation there is provided a kind of above-mentioned mark compositions The purposes to come to an end in core latent infection and/or active tuberculosis product.
Another aspect of the present invention there is provided one kind for differentiate, diagnose and/or screening tuberculosis latent infection and/or The kit of active tuberculosis, the kit include Rv0284 albumen, Rv2002 albumen and/or Rv2421c albumen.
Preferably, the Rv0284 albumen is the amino acid sequence shown in SEQ ID NO.1 or shown in SEQ ID NO.1 Albumen shown in the engineered rear and SEQ ID NO.1 of one or several amino acid residues in row has the protein of identical function； The Rv2002 albumen is one or several ammonia in the amino acid sequence shown in SEQ ID NO.2 or shown in SEQ ID NO.2 Albumen has the protein of identical function after base acid residue is engineered and shown in SEQ ID NO.2；The Rv2421c albumen is After one or several amino acid residues in amino acid sequence shown in SEQ ID NO.3 or shown in SEQ ID NO.3 are engineered There is the protein of identical function with albumen shown in SEQ ID NO.3.
Rv0284 albumen, Rv2002 albumen and/or the Rv2421c albumen included in mentioned reagent box can be arbitrary shape Formula, including but not limited to direct protein example and by proteinaceous solid due to certain carrier, such as the form of detection chip.
Other than Rv0284 albumen, Rv2002 albumen and/or Rv2421c albumen, the kit at least further includes examination Agent box specification.
The criterion of result described in the specification：Using three kinds of albumen joint-detections, if the detection of sample to be tested As a result in, in anti-Rv0284 antibody, anti-Rv2002 antibody and/or anti-Rv2421c antibody, at least 2 kinds of antibodies positives are then sentenced The fixed sample to be tested is the active tuberculosis positive, is otherwise tuberculosis latent infection.
Another aspect of the present invention is there is provided a kind of mentioned reagent box in preparation discriminating, diagnosis and/or screening tuberculosis Purposes in latent infection and/or active tuberculosis product.
Beneficial effects of the present invention are：
The present invention can detect the level of three different mycobacterium tuberculosis protein serum antibody responses simultaneously, so as to Preferably antidiastole tuberculosis latent infection person and active tuberculosis patient, sensitivity higher, specificity are more preferable.
Description of the drawings
Fig. 1 is detected for ELISA in tuberculosis latent infection person (n=93) and active tuberculosis patient (n=92) serum The statistical chart of anti-Rv0284 antibody, anti-Rv2002 antibody and anti-Rv2421c antibody expressions；
Fig. 2 is the ROC curve figure of the corresponding antibody of three antigens of joint-detection；
Sequence explanation
SEQ ID NO.1 are the amino acid sequence of the Rv0284 albumen in the embodiment of the present invention；
SEQ ID NO.2 are the amino acid sequence of the Rv2002 albumen in the embodiment of the present invention；
SEQ ID NO.3 are the amino acid sequence of the Rv2421c albumen in the embodiment of the present invention.
Specific embodiment
The invention discloses a kind of detection sample moderate resistance Rv0284 antibody, anti-Rv2002 antibody and/or anti-Rv2421c antibody Purposes of the horizontal product in preparation discriminating, diagnosis and/or screening tuberculosis latent infection and/or active tuberculosis product. Those skilled in the art can use for reference present disclosure, be suitably modified technological parameter realization.It is it is important to note that all similar Replacement and change it is apparent to those skilled in the art, they are considered as being included in the present invention, and phase Pass personnel can significantly be modified content described herein on the basis of the content of present invention, spirit and scope are not departed from or suitably Change is with combining, to realize and using the technology of the present invention.
In the present invention, unless otherwise stated, Science and Technology noun used herein has art technology The normally understood meaning of personnel institute.
In order to which those skilled in the art is made to more fully understand technical scheme of the present invention, with reference to specific embodiment pair The present invention is described in further detail.
Embodiment 1：The collection and processing of sample
The sample that the present invention detects is serum, and collection method is acquisition subject's blood on an empty stomach, using being not added with anti-coagulants Common biochemistry test tube, is stored at room temperature after natural coagulation, is centrifuged 10 minutes with 3000 rpms of room temperature, is collected serum and is sub-packed in Cryopreservation tube is positioned over -80 degrees Celsius of low temperature refrigerators and preserves, and uses when testing.
The sample that the present invention uses is divided into two groups：Latent infection group and active tuberculosis patient's group；Wherein, latent infection group Refer to without clinical chief complaint, TST experiments and T-SPOT experiments are the positive, C-XF negative patient；Active tuberculosis patient Group refers to positive through smear or culture, does not start or just start cycle chemistry drug therapy makes a definite diagnosis tuberculosis patient；Two groups of crowds Exclude diabetes, HIV infection and other autoimmune diseases.
The latent infection group sample that the present invention uses comes from Beijing Tuberculosis and Thoracic Tumor Research Institute's epidemiological study Room epidemiological survey project, active tuberculosis patient organize sample and come from attached BJ Chest Science Hospital's tuberculosis section of the Capital University of Medical Sciences Each lesion inpatient, this subject have obtained the approval of attached BJ Chest Science Hospital's Research papers committee of the Capital University of Medical Sciences, All equal informed consents of research object.
Embodiment 2：The detection to sample is tested using ELISA
1. establish various buffer solutions, dilution, reaction solution and the terminate liquid needed for ELSIA experiments：
(1) coating buffer solution (carbonate buffer solution of pH9.6,0.05mol/L)：
Na2CO31.59g NaHCO32.93g adds distilled water to adjust pH to 9.6 to 1000ml；
(2) PBS solution of pH7.4：
NaCl 8.0g, KCl 0.2g, KH2PO40.2g, Na2HPO4·12H2O 2.9g,
Distilled water is added to adjust pH to 7.4 to 1000ml；
(3) the PBST cleaning solutions of pH7.4：
Tween-20 0.5ml are added in 1000mlPBS solution, adjust pH to 7.4；
(4) confining liquid (PBS solution of the pH7.4 containing skimmed milk power)：
5g skimmed milk powers are added in 100mlPBS solution；
(5) substrate buffer solution：0.2M NaH2PO4(28.4g/L) 25.7ml,
0.1M citric acids (19.2g/L) 24.3ml, adds distilled water 50ml.
(6) TMB (tetramethyl benzidine) uses liquid:TMB (10mg/5ml absolute ethyl alcohols) 0.5ml substrate buffer solutions (pH5.5) 10ml 0.75%H2O232μl；
(7) terminate liquid (2M H2SO4)：21.32ml H2SO4, 178.68ml H2O。
(8) secondary antibody：The Goat anti-Human IgG of horseradish peroxidase (HRP) label；
(9) 96 hole elisa Plates；Nunc Incorporated(Theromo,Gebenhagen,Denmark)
2. detecting step：
(1) it is coated with：Rv0284, Rv2002 and Rv2421c antigen are dissolved separately in coating buffer solution (5ug/ml)；With 100ul/ holes are added in 96 hole elisa Plates, and 4 DEG C overnight；
(2) board-washing：PBST cleaning solution 300ul/ holes, 3min are washed 3 times；
(3) it closes：Confining liquid, 300ul/ holes are incubated at room temperature 1h；
(4) board-washing：Cleaning solution 300ul/ holes, 3min are washed 3 times；
(5) increase serum：By 1:Test serum after 400 dilutions, 100ul/ holes are incubated at room temperature 1h；
(6) board-washing：Cleaning solution 300ul/ holes, 3min are washed 5 times；
(7) add ELIAS secondary antibody：The enzyme labelled antibody (1 of diluted fresh:30000) 100ul/ holes are incubated at room temperature 1h；
(8) board-washing：Cleaning solution 300ul/ holes, 3min are washed 5 times；
(9) it develops the color：The TMB developing solutions of fresh configuration, 100ul/ holes, room temperature, which is protected from light, is incubated 5-10min；
(10) it terminates：Terminate liquid 2M H2SO4, 50ul/ holes；
(11) it measures：Microplate reader is adjusted to 450nm, and each hole OD values are surveyed after returning to zero with first blank PBS control hole.
3. interpretation of result and criterion：
Using SPSS22.0 Software on Drawing ROC curves, according to coordinate value, obtain specificity corresponding to different critical point and Then susceptibility calculates youden index (youden index=specificity+susceptibility -1), obtain the critical point OD values point of three kinds of antigen It is not Rv0248 0.3475, Rv2002 0.3048, Rv2421c 0.4173；
The results are shown in Figure 1, the results showed that, three albumen are respectively provided with the work for distinguishing tuberculosis latent infection and active tuberculosis With.
Criterion：
Using three kinds of albumen joint-detections, if in the testing result of sample to be tested, anti-Rv0284 antibody, anti-Rv2002 antibody And/or in anti-Rv2421c antibody, at least 2 kinds of antibodies positives, then it is the active tuberculosis positive to judge the sample to be tested, no It is then tuberculosis latent infection.
Embodiment 3：Using the specific and quick of the method for ELISA antidiastole active tuberculosis patients and latent infection person Perception
Use patients serum 92 part of the clinical diagnosis for active tuberculosis, 93 parts of latent infection person serum；Utilize implementation ELISA method in example 1 and 2 is detected, and judges whether person under test is active tuberculosis by the criterion of embodiment 2 The positive, the results are shown in Figure 2, and interpretation of result specificity is 83.87%, sensibility 79.35%.Abscissa 1- is special in Fig. 2 Degree represents false positive rate, ordinate sensitive representations true positive rate.
Result above proves the level of the different mycobacterium tuberculosis protein serum antibody responses of present invention detection three, can be with Preferably antidiastole tuberculosis latent infection person and active tuberculosis patient, sensitivity higher, specificity are more preferable.
The above is only the preferred embodiment of the present invention, it is noted that for the ordinary skill people of the art For member, various improvements and modifications may be made without departing from the principle of the present invention, these improvements and modifications also should It is considered as protection scope of the present invention.
SEQUENCE LISTING
<110>Attached BJ Chest Science Hospital of the Capital University of Medical Sciences
<120>Mycobacterium tuberculosis protein is preparing diagnosis of tuberculosis latent infection person and/or active tuberculosis product
In purposes
<130> None
<160> 3
<170> PatentIn version 3.5
<210> 1
<211> 645
<212> PRT
<213>Mycobacterium tuberculosis
<400> 1
Met Val Glu Val Glu Arg His Ser Tyr Asp Val Val Val Ile Gly Ala
1 5 10 15
Gly Gly Ala Gly Leu Arg Ala Val Ile Glu Ala Arg Glu Arg Gly Leu
20 25 30
Lys Val Ala Val Val Cys Lys Ser Leu Phe Gly Lys Ala His Thr Val
35 40 45
Met Ala Glu Gly Gly Cys Ala Ala Ala Met Gly Asn Ala Asn Pro Lys
50 55 60
Asp Asn Trp Lys Thr His Phe Gly Asp Thr Met Arg Gly Gly Lys Phe
65 70 75 80
Leu Asn Asn Trp Arg Met Ala Glu Leu His Ala Lys Glu Ala Pro Asp
85 90 95
Arg Val Trp Glu Leu Glu Thr Tyr Gly Ala Leu Phe Asp Arg Thr Asp
100 105 110
Asp Gly Arg Ile Ser Gln Arg Asn Phe Gly Gly His Thr Tyr Pro Arg
115 120 125
Leu Ala His Val Gly Asp Arg Thr Gly Leu Glu Leu Ile Arg Thr Leu
130 135 140
Gln Gln Lys Val Val Ser Leu Gln Gln Glu Asp His Ala Glu Leu Gly
145 150 155 160
Asp Tyr Glu Ala Arg Ile Lys Val Phe Ala Glu Cys Thr Ile Thr Glu
165 170 175
Leu Leu Lys Asp Gln Gly Ala Ile Ala Gly Ala Phe Gly Tyr Trp Arg
180 185 190
Glu Ser Gly Arg Phe Ile Val Phe Glu Ala Pro Ala Val Val Leu Ala
195 200 205
Thr Gly Gly Ile Gly Lys Ser Phe Lys Val Thr Ser Asn Ser Trp Glu
210 215 220
Tyr Thr Gly Asp Gly His Ala Leu Ala Leu Arg Ala Gly Ala Thr Leu
225 230 235 240
Asn Met Glu Phe Val Gln Phe His Pro Thr Gly Met Val Trp Pro Pro
245 250 255
Ser Val Lys Gly Ile Leu Val Thr Glu Gly Val Arg Gly Asp Gly Gly
260 265 270
Val Leu Lys Asn Ser Glu Asn Ser Arg Phe Met Phe Asp Tyr Ile Pro
275 280 285
Pro Val Phe Lys Gly Gln Tyr Ala Glu Thr Glu Glu Glu Ala Asp Gln
290 295 300
Trp Leu Lys Asp Asn Asp Ser Ala Arg Arg Thr Pro Asp Leu Leu Pro
305 310 315 320
Arg Asp Glu Val Ala Arg Ala Ile Asn Ser Glu Val Lys Ala Gly Arg
325 330 335
Gly Thr Pro His Gly Gly Val Tyr Leu Asp Ile Ala Ser Arg Leu Thr
340 345 350
Pro Ala Glu Ile Lys Arg Arg Leu Pro Ser Met Tyr His Gln Phe Lys
355 360 365
Glu Leu Ala Glu Val Asp Ile Thr Thr Gln Ala Met Glu Val Gly Pro
370 375 380
Thr Cys His Tyr Val Met Gly Gly Val Glu Val Asp Ala Asp Thr Gly
385 390 395 400
Ala Ala Thr Val Pro Gly Leu Phe Ala Ala Gly Glu Cys Ala Gly Gly
405 410 415
Met His Gly Ser Asn Arg Leu Gly Gly Asn Ser Leu Ser Asp Leu Leu
420 425 430
Val Phe Gly Arg Arg Ala Gly Leu Gly Ala Ala Asp Tyr Val Arg Ala
435 440 445
Leu Ser Ser Arg Pro Ala Val Ser Ala Glu Ala Ile Asp Ala Ala Ala
450 455 460
Gln Gln Ala Leu Ser Pro Phe Glu Gly Pro Lys Asp Gly Ser Ala Pro
465 470 475 480
Glu Asn Pro Tyr Ala Leu His Met Asp Leu Gln Tyr Val Met Asn Asp
485 490 495
Leu Val Gly Ile Ile Arg Asn Ala Asp Glu Ile Ser Arg Ala Leu Thr
500 505 510
Leu Leu Ala Glu Leu Trp Ser Arg Tyr His Asn Val Leu Val Glu Gly
515 520 525
His Arg Gln Tyr Asn Pro Gly Trp Asn Leu Ser Ile Asp Leu Arg Asn
530 535 540
Met Leu Leu Val Ser Glu Cys Val Ala Arg Ala Ala Leu Gln Arg Thr
545 550 555 560
Glu Ser Arg Gly Gly His Thr Arg Asp Asp His Pro Gly Met Asp Pro
565 570 575
Asn Trp Arg Arg Ile Leu Leu Val Cys Arg Ala Thr Glu Thr Met Gly
580 585 590
Thr Gly Gly Ser Gly Ser Gly Asp Ser Asn Cys His Ile Asn Val Thr
595 600 605
Gln Gln Leu Gln Thr Pro Met Arg Pro Asp Leu Leu Glu Leu Phe Glu
610 615 620
Ile Ser Glu Leu Glu Lys Tyr Tyr Thr Asp Glu Glu Leu Ala Glu His
625 630 635 640
Pro Gly Arg Arg Gly
645
<210> 2
<211> 260
<212> PRT
<213>Mycobacterium tuberculosis
<400> 2
Met Ser Gly Arg Leu Ile Gly Lys Val Ala Leu Val Ser Gly Gly Ala
1 5 10 15
Arg Gly Met Gly Ala Ser His Val Arg Ala Met Val Ala Glu Gly Ala
20 25 30
Lys Val Val Phe Gly Asp Ile Leu Asp Glu Glu Gly Lys Ala Val Ala
35 40 45
Ala Glu Leu Ala Asp Ala Ala Arg Tyr Val His Leu Asp Val Thr Gln
50 55 60
Pro Ala Gln Trp Thr Ala Ala Val Asp Thr Ala Val Thr Ala Phe Gly
65 70 75 80
Gly Leu His Val Leu Val Asn Asn Ala Gly Ile Leu Asn Ile Gly Thr
85 90 95
Ile Glu Asp Tyr Ala Leu Thr Glu Trp Gln Arg Ile Leu Asp Val Asn
100 105 110
Leu Thr Gly Val Phe Leu Gly Ile Arg Ala Val Val Lys Pro Met Lys
115 120 125
Glu Ala Gly Arg Gly Ser Ile Ile Asn Ile Ser Ser Ile Glu Gly Leu
130 135 140
Ala Gly Thr Val Ala Cys His Gly Tyr Thr Ala Thr Lys Phe Ala Val
145 150 155 160
Arg Gly Leu Thr Lys Ser Thr Ala Leu Glu Leu Gly Pro Ser Gly Ile
165 170 175
Arg Val Asn Ser Ile His Pro Gly Leu Val Lys Thr Pro Met Thr Asp
180 185 190
Trp Val Pro Glu Asp Ile Phe Gln Thr Ala Leu Gly Arg Ala Ala Glu
195 200 205
Pro Val Glu Val Ser Asn Leu Val Val Tyr Leu Ala Ser Asp Glu Ser
210 215 220
Ser Tyr Ser Thr Gly Ala Glu Phe Val Val Asp Gly Gly Thr Val Ala
225 230 235 240
Gly Leu Ala His Asn Asp Phe Gly Ala Val Glu Val Ser Ser Gln Pro
245 250 255
Glu Trp Val Thr
260
<210> 3
<211> 211
<212> PRT
<213>Mycobacterium tuberculosis
<400> 3
Met Gly Gly Thr Phe Asp Pro Ile His Tyr Gly His Leu Val Ala Ala
1 5 10 15
Ser Glu Val Ala Asp Leu Phe Asp Leu Asp Glu Val Val Phe Val Pro
20 25 30
Ser Gly Gln Pro Trp Gln Lys Gly Arg Gln Val Ser Ala Ala Glu His
35 40 45
Arg Tyr Leu Met Thr Val Ile Ala Thr Ala Ser Asn Pro Arg Phe Ser
50 55 60
Val Ser Arg Val Asp Ile Asp Arg Gly Gly Pro Thr Tyr Thr Lys Asp
65 70 75 80
Thr Leu Ala Asp Leu His Ala Leu His Pro Asp Ser Glu Leu Tyr Phe
85 90 95
Thr Thr Gly Ala Asp Ala Leu Ala Ser Ile Met Ser Trp Gln Gly Trp
100 105 110
Glu Glu Leu Phe Glu Leu Ala Arg Phe Val Gly Val Ser Arg Pro Gly
115 120 125
Tyr Glu Leu Arg Asn Glu His Ile Thr Ser Leu Leu Gly Gln Leu Ala
130 135 140
Lys Asp Ala Leu Thr Leu Val Glu Ile Pro Ala Leu Ala Ile Ser Ser
145 150 155 160
Thr Asp Cys Arg Gln Arg Ala Glu Gln Ser Arg Pro Leu Trp Tyr Leu
165 170 175
Met Pro Asp Gly Val Val Gln Tyr Val Ser Lys Cys Arg Leu Tyr Cys
180 185 190
Gly Ala Cys Asp Ala Gly Ala Arg Ser Thr Thr Ser Leu Ala Ala Gly
195 200 205
Asn Gly Leu
210

Claims (10)

1. the product for detecting sample moderate resistance Rv0284 antibody, anti-Rv2002 antibody and/or anti-Rv2421c antibody levels is preparing mirror Not, diagnosis and/or screening tuberculosis latent infection and/or active tuberculosis product in purposes.
2. purposes according to claim 1, described to detect sample moderate resistance Rv0284 antibody, anti-Rv2002 antibody and/or resist The product of Rv2421c antibody levels includes Rv0284 albumen, Rv2002 albumen and/or Rv2421c albumen.
3. purposes according to claim 2, which is characterized in that the Rv0284 albumen be shown in SEQ ID NO.1 or Shown in the engineered rear and SEQ ID NO.1 of one or several amino acid residues in amino acid sequence shown in SEQ ID NO.1 Albumen has the protein of identical function；The Rv2002 albumen is shown in SEQ ID NO.2 or shown in SEQ ID NO.2 Albumen shown in the engineered rear and SEQ ID NO.2 of one or several amino acid residues in amino acid sequence has identical function Protein；The Rv2421c albumen is one in the amino acid sequence shown in SEQ ID NO.3 or shown in SEQ ID NO.3 Or albumen shown in several engineered rear and SEQ ID NO.3 of amino acid residue has the protein of identical function.
4. according to the purposes described in any one in claim 1-3, which is characterized in that the method for the detection includes enzyme-linked exempt from Epidemic disease adsorption test, aggegation experiment, precipitation experiments, the experiment of E garlands, small phagocytosis experiment, immunofluorescence experiment, colloidal gold immunochromatographimethod Experiment, dot immuno gold filtration assay experiment and/or electrochemiluminescence assay.
5. according to the purposes described in any one in claim 1-3, which is characterized in that the sample includes serum, blood plasma, saliva Liquid, urine, Pleural effusions and/or cerebrospinal fluid.
6. it is a kind of for differentiating, diagnosing and/or the mark compositions of screening tuberculosis latent infection and/or active tuberculosis, It is characterized in that, the mark compositions are made of anti-Rv0284 antibody, anti-Rv2002 antibody and/or anti-Rv2421c antibody；
Wherein, the Rv0284 be one in amino acid sequence shown in SEQ ID NO.1 or shown in SEQ ID NO.1 or Albumen has the protein of identical function after several amino acid residues are engineered and shown in SEQ ID NO.1；The Rv2002 is After one or several amino acid residues in amino acid sequence shown in SEQ ID NO.2 or shown in SEQ ID NO.2 are engineered There is the protein of identical function with albumen shown in SEQ ID NO.2；The Rv2421c is shown in SEQ ID NO.3 or SEQ Albumen shown in the engineered rear and SEQ ID NO.3 of one or several amino acid residues in amino acid sequence shown in ID NO.3 Protein with identical function.
7. a kind of mark compositions as claimed in claim 6 are preparing discriminating, diagnosis and/or screening tuberculosis latent infection And/or the purposes in active tuberculosis product.
8. a kind of for differentiating, diagnosing and/or the kit of screening tuberculosis latent infection and/or active tuberculosis, feature It is, the kit includes Rv0284 albumen, Rv2002 albumen and/or Rv2421c albumen.
9. kit according to claim 8, which is characterized in that the Rv0284 albumen be shown in SEQ ID NO.1 or Shown in the engineered rear and SEQ ID NO.1 of one or several amino acid residues in amino acid sequence shown in SEQ ID NO.1 Albumen has the protein of identical function；The Rv2002 albumen is shown in SEQ ID NO.2 or shown in SEQ ID NO.2 Albumen shown in the engineered rear and SEQ ID NO.2 of one or several amino acid residues in amino acid sequence has identical function Protein；The Rv2421c albumen is one in the amino acid sequence shown in SEQ ID NO.3 or shown in SEQ ID NO.3 Or albumen shown in several engineered rear and SEQ ID NO.3 of amino acid residue has the protein of identical function.
10. a kind of kit as claimed in claim 8 or 9 prepare differentiate, diagnosis and/or screening tuberculosis latent infection and/ Or the purposes in active tuberculosis product.
CN201611259564.2A 2016-12-30 2016-12-30 Application of mycobacterium tuberculosis protein in preparing product for diagnosing latent tuberculosis infected person and/or active tuberculosis Active CN108267589B (en)

Priority Applications (3)

Application Number Priority Date Filing Date Title
CN202010371686.0A CN111521819B (en) 2016-12-30 2016-12-30 Use of mycobacterium tuberculosis proteins in the preparation of a product for diagnosing tuberculosis latency infected persons and/or active tuberculosis
CN202010371675.2A CN111551741B (en) 2016-12-30 2016-12-30 Use of mycobacterium tuberculosis proteins in the preparation of a product for diagnosing tuberculosis latency infected persons and/or active tuberculosis
CN201611259564.2A CN108267589B (en) 2016-12-30 2016-12-30 Application of mycobacterium tuberculosis protein in preparing product for diagnosing latent tuberculosis infected person and/or active tuberculosis

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN201611259564.2A CN108267589B (en) 2016-12-30 2016-12-30 Application of mycobacterium tuberculosis protein in preparing product for diagnosing latent tuberculosis infected person and/or active tuberculosis

Related Child Applications (2)

Application Number Title Priority Date Filing Date
CN202010371675.2A Division CN111551741B (en) 2016-12-30 2016-12-30 Use of mycobacterium tuberculosis proteins in the preparation of a product for diagnosing tuberculosis latency infected persons and/or active tuberculosis
CN202010371686.0A Division CN111521819B (en) 2016-12-30 2016-12-30 Use of mycobacterium tuberculosis proteins in the preparation of a product for diagnosing tuberculosis latency infected persons and/or active tuberculosis

Publications (2)

Publication Number Publication Date
CN108267589A true CN108267589A (en) 2018-07-10
CN108267589B CN108267589B (en) 2020-10-23

Family

ID=62754940

Family Applications (3)

Application Number Title Priority Date Filing Date
CN202010371675.2A Active CN111551741B (en) 2016-12-30 2016-12-30 Use of mycobacterium tuberculosis proteins in the preparation of a product for diagnosing tuberculosis latency infected persons and/or active tuberculosis
CN201611259564.2A Active CN108267589B (en) 2016-12-30 2016-12-30 Application of mycobacterium tuberculosis protein in preparing product for diagnosing latent tuberculosis infected person and/or active tuberculosis
CN202010371686.0A Active CN111521819B (en) 2016-12-30 2016-12-30 Use of mycobacterium tuberculosis proteins in the preparation of a product for diagnosing tuberculosis latency infected persons and/or active tuberculosis

Family Applications Before (1)

Application Number Title Priority Date Filing Date
CN202010371675.2A Active CN111551741B (en) 2016-12-30 2016-12-30 Use of mycobacterium tuberculosis proteins in the preparation of a product for diagnosing tuberculosis latency infected persons and/or active tuberculosis

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN202010371686.0A Active CN111521819B (en) 2016-12-30 2016-12-30 Use of mycobacterium tuberculosis proteins in the preparation of a product for diagnosing tuberculosis latency infected persons and/or active tuberculosis

Country Status (1)

Country Link
CN (3) CN111551741B (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111157745A (en) * 2020-01-17 2020-05-15 上海交通大学 Application of human SNRPA protein in lung cancer recurrence or metastasis monitoring

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007131291A1 (en) * 2006-05-16 2007-11-22 Proteome Systems Limited Methods of diagnosis and treatment of m. tuberculosis infection and reagents therefore
CN101203239A (en) * 2005-03-31 2008-06-18 莱顿大学医药中心 Methods and means for diagnostics, prevention and treatment of mycobacterium infections and tuberculosis disease
CN101294964A (en) * 2007-11-27 2008-10-29 复旦大学附属华山医院 Reagent and method for detecting active tuberculosis and tuberculosis dormant infection
CN103698530A (en) * 2013-11-25 2014-04-02 广东体必康生物科技有限公司 Application of mycobacterium tuberculosis protein in preparation of products used for diagnosis of active tuberculosis
EP2417456B1 (en) * 2009-04-09 2016-07-06 Ajit Lalvani Diagnostic mycobacterium tuberculosis test

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2405247A1 (en) * 2000-04-19 2001-10-25 Statens Serum Institut Tuberculosis antigens and methods of use thereof
EP1354207A2 (en) * 2000-12-29 2003-10-22 Triad Therapeutics, Inc. Prediction of functional and structural properties of polypeptides
US20060182685A1 (en) * 2004-09-04 2006-08-17 Bishai William R Hollow fiber technique for in vivo study of cell populations
WO2008134806A1 (en) * 2007-05-04 2008-11-13 The University Of Sydney Mycobacterium antigens
WO2009039854A2 (en) * 2007-09-27 2009-04-02 Dako Denmark A/S Mhc multimers in tuberculosis diagnostics, vaccine and therapeutics
US8361482B2 (en) * 2007-11-27 2013-01-29 Aeras Global Tb Vaccine Foundation Recombinant BCG tuberculosis vaccine designed to elicit immune responses to mycobacterium tuberculosis in all physiological stages of infection and disease
US7670609B2 (en) * 2007-11-27 2010-03-02 Aeras Global Tb Vaccine Foundation Recombinant BCG tuberculosis vaccine designed to elicit immune responses to Mycobacterium tuberculosis in all physiological stages of infection and disease
CN101493454A (en) * 2008-01-21 2009-07-29 范雄林 Tuberculosis antigen specific whole blood IFN-gamma diagnosis kit, method for producing the same and method for using same
CN102590502B (en) * 2012-01-11 2014-07-02 北京市结核病胸部肿瘤研究所 Kit for auxiliary diagnosis of tuberculosis patients
CN105388297B (en) * 2013-11-25 2017-06-06 广东体必康生物科技有限公司 Purposes of the Mycobacterium tuberculosis albumen Rv1984c in the product for preparing diagnosis latent tuberculosis infection
WO2016046734A2 (en) * 2014-09-22 2016-03-31 University Of The Western Cape Compounds and compositions for treatment of tuberculosis
CN105588944B (en) * 2016-02-25 2017-05-24 首都医科大学附属北京胸科医院 Application of AGP1, SERPINA3 and CDH1 content detection system in screening active tuberculosis patients

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101203239A (en) * 2005-03-31 2008-06-18 莱顿大学医药中心 Methods and means for diagnostics, prevention and treatment of mycobacterium infections and tuberculosis disease
WO2007131291A1 (en) * 2006-05-16 2007-11-22 Proteome Systems Limited Methods of diagnosis and treatment of m. tuberculosis infection and reagents therefore
CN101294964A (en) * 2007-11-27 2008-10-29 复旦大学附属华山医院 Reagent and method for detecting active tuberculosis and tuberculosis dormant infection
EP2417456B1 (en) * 2009-04-09 2016-07-06 Ajit Lalvani Diagnostic mycobacterium tuberculosis test
CN103698530A (en) * 2013-11-25 2014-04-02 广东体必康生物科技有限公司 Application of mycobacterium tuberculosis protein in preparation of products used for diagnosis of active tuberculosis

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
KERSTINJ.WILLIAMS，ET AL: "Deciphering the metabolic response of Mycobacterium tuberculosis to nitrogen stress", 《MOLECULAR MICROBIOLOGY》 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111157745A (en) * 2020-01-17 2020-05-15 上海交通大学 Application of human SNRPA protein in lung cancer recurrence or metastasis monitoring

Also Published As

Publication number Publication date
CN108267589B (en) 2020-10-23
CN111551741B (en) 2023-06-16
CN111521819A (en) 2020-08-11
CN111521819B (en) 2023-06-20
CN111551741A (en) 2020-08-18

Similar Documents

Publication Publication Date Title
Deplazes et al. An enzyme-linked immunosorbent assay for diagnostic detection of Taenia saginata copro-antigens in humans
Boone et al. TechLab and Alexon Giardia enzyme-linked immunosorbent assay kits detect cyst wall protein 1
Sawangsoda et al. Diagnostic values of parasite-specific antibody detections in saliva and urine in comparison with serum in opisthorchiasis
Xiao et al. The Toxoplasma MAG1 peptides induce sex-based humoral immune response in mice and distinguish active from chronic human infection
Zhu et al. Application of dipstick dye immunoassay (DDIA) kit for the diagnosis of schistosomiasis mekongi
EP2612149A2 (en) Compositions and methods for diagnosing and monitoring disease and treatment via antigen-specific molecules
Sathyanarayan et al. A comparative study of agglutination tests, blood culture & ELISA in the laboratory diagnosis of human brucellosis
Gottstein et al. An international study on the serological differential diagnosis of human cystic and alveolar echinococcocis
CN108267589A (en) Purposes of the mycobacterium tuberculosis protein in diagnosis of tuberculosis latent infection person and/or active tuberculosis product is prepared
McConkey S et al. Evaluation of a rapid-format antibody test and the tuberculin skin test for diagnosis of tuberculosis in two contrasting endemic settings
Xifeng et al. Development and evaluation of a colloidal gold immunochromatographic assay based on recombinant protein CatL1D for serodiagnosis of sheep fasciolosis
JP2019508684A (en) Methods and kits for the diagnosis of active tuberculosis
CN108267588A (en) Purposes of the mycobacterium tuberculosis protein in diagnosis of tuberculosis latent infection person and/or active tuberculosis product is prepared
CN109061191A (en) Application of the S100P albumen as marker in diagnostic activities tuberculosis
Kaur et al. Diagnostic accuracy of rapid enzyme linked immunosorbent assay for the diagnosis of human hydatidosis
Cheng et al. Amoebiasis among institutionalized psychiatric patients in Taiwan
KR102132964B1 (en) Method for Diagnosing Scrub Typhus Using Exosome derived from Orientia tsutsugamushi
Coates et al. Identification of Mycobacterium tuberculosis antigens in Seibert fractions by immunoblotting
Ma et al. A filtration-based rapid test using a partially purified third-stage larval antigen to detect specific antibodies for the diagnosis of gnathostomiasis
CN107202882B (en) Purposes of the Rv0440 albumen in diagnosis latency/active tuberculosis
Ando et al. Imported African tick bite fever in Japan: A literature review and report of three cases
Tran et al. Clinical Utility of Combined Whole-cell Antigen and Recombinant Hemolysis Co-regulated Protein 1-Enzyme-linked Immunosorbent Assays Reveals Underdiagnosed Cases of Melioidosis in Vietnam
Poussin et al. Capture-ELISA: a new assay for the detection of immunoglobulin M isotype antibodies using Chlamydia trachomatis antigen
Gandhi et al. Enzyme linked protein-A: An ELISA for detection of IgG antibodies against Mycobacterium tuberculosis in intestinal tuberculosis
Rabiu et al. Tuberculosis an Opportunistic Infection

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant